Secobarbital and nocturnal physiological patterns

Summary Sleep patterns of 14 male Ss were examined following a single oral dose (200 mg) of the barbiturate secobarbital. Compared to baseline, medication caused definite changes in the amount and distribution of the EEG stages of sleep. With the drug, a decrease in percent stage REM and an increase in percent stage 2 were accompanied by fewer body movements and a trend toward less waking. A more striking effect was the drug-induced redistribution of EEG stages with slow-wave sleep potentiated during the first half of the night but virtually eliminated during the last half. Stage REM, on the other hand, was inhibited in the first half but returned to baseline levels in the last half of the night. Recent evidence suggests that such effects could result from modulation of brain levels of the monoamines.Within the stages of sleep the amount of fast EEG activity was increased by the drug, with a tendency toward desynchrony. Pre-central beta activity became especially prominent in stages REM and 2 (low-voltage phases), and this change was associated with inhibition of such phasic events as eye movements during REM sleep, sigma spindles during stage 2 and spontaneous electrodermal responses in slow-wave sleep. Thus, it appears that secobarbital potentiates tonic and suppresses phasic phenomena during sleep. A possible interpretation of these results is that secobarbital enhances electrical activity in forebrain structures (Routtenberg's arousal system II) while inhibiting the reticular activating system (arousal system I) causing a reduction of phasic variability in all stages of sleep.We wish to thank O. H. Rundell and Joe Gold for their assistance in data acquisition and management of the experiment, and Rosa Coulter, Cindy Williams and Maria Chan for their invaluable contributions to data reduction and statistical analysis.